TY - JOUR
T1 - Comparison of short-term outcome and serum magnesium levels in premature infants of mothers after magnesium sulfate therapy
AU - Aditiawarman,
AU - Salean, Jacob Trisusilo
AU - Sampurna, Mahendra Tri Arif
AU - Ernawati,
AU - Joewono, Hermanto Tri
N1 - Publisher Copyright:
© 2020 Aditiawarman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: Magnesium sulfate (MgSO4) is proven to be a neuroprotectant which functions to reduce the risk of cerebral palsy in premature infants, but the effects on the short-term outcome of newborns are still contradictory. This study aimed to analyze differences in short-term outcomes and serum magnesium levels in newborns after given MgSO4 therapy. Methods: This was a prospective cohort study. Subjects were divided into two groups involved preterm infants from mothers who received MgSO4 and pregnant women who did not received MgSO4 as a control. Results: Among sixty subjects, there were significant differences in outcomes for gestational age infants and respiratory distress syndrome (RDS) between two groups (p = 0.011 and p = 0.013, respectively). Whereas, the significance results were found in birth weight (p = 0.306), Apgar scores 1 (p = 0.816) and 5 minutes (p = 0.924), the use of ventilators (p = 0.335), sepsis (p = 0.276), mortality (p = 0.754), and umbilical artery pH (p = 0.123). The magnesium serum levels of mothers who received MgSO4 and control were 3.45±1.65 mg/dl and 1.78±0.23 mg/dl, respectively (p = 0.001), and infants who received MgSO4 and control were 3.10±1.35 mg/dl and 1.74±0.19 mg/dl, respectively (p = 0.001). Conclusion: There were significant differences in infant outcomes only at gestational age and RDS. The magnesium serum levels of newborns in therapy group were higher than control.
AB - Background: Magnesium sulfate (MgSO4) is proven to be a neuroprotectant which functions to reduce the risk of cerebral palsy in premature infants, but the effects on the short-term outcome of newborns are still contradictory. This study aimed to analyze differences in short-term outcomes and serum magnesium levels in newborns after given MgSO4 therapy. Methods: This was a prospective cohort study. Subjects were divided into two groups involved preterm infants from mothers who received MgSO4 and pregnant women who did not received MgSO4 as a control. Results: Among sixty subjects, there were significant differences in outcomes for gestational age infants and respiratory distress syndrome (RDS) between two groups (p = 0.011 and p = 0.013, respectively). Whereas, the significance results were found in birth weight (p = 0.306), Apgar scores 1 (p = 0.816) and 5 minutes (p = 0.924), the use of ventilators (p = 0.335), sepsis (p = 0.276), mortality (p = 0.754), and umbilical artery pH (p = 0.123). The magnesium serum levels of mothers who received MgSO4 and control were 3.45±1.65 mg/dl and 1.78±0.23 mg/dl, respectively (p = 0.001), and infants who received MgSO4 and control were 3.10±1.35 mg/dl and 1.74±0.19 mg/dl, respectively (p = 0.001). Conclusion: There were significant differences in infant outcomes only at gestational age and RDS. The magnesium serum levels of newborns in therapy group were higher than control.
KW - MgSO4
KW - Premature infant
KW - Short-term outcome
UR - http://www.scopus.com/inward/record.url?scp=85090666392&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85090666392
SN - 1307-9867
VL - 14
SP - 1863
EP - 1867
JO - EurAsian Journal of BioSciences
JF - EurAsian Journal of BioSciences
IS - 1
ER -